27758943|t|Renal Function and the Risk of Stroke and Bleeding in Patients With Atrial Fibrillation: An Observational Cohort Study
27758943|a|We sought to determine the risk of stroke / thromboembolism and bleeding associated with reduced renal function in patients with atrial fibrillation and the risk of stroke and bleeding associated with warfarin treatment in specific estimated glomerular filtration rate (eGFR) groups. We conducted a register-based cohort study and included patients discharged with nonvalvular atrial fibrillation from 1997 to 2011 with available eGFR. A total of 17 349 patients were identified with eGFR available at baseline. All levels of lower eGFR were associated with higher risk of stroke / thromboembolism and bleeding. Use of warfarin was associated with higher bleeding risk in all eGFR groups; hazard ratios 1.23 (95% confidence interval [CI], 0.97-1.56), 1.26 (95% CI, 1.14-1.40), 1.18 (95% CI, 1.07-1.31), 1.11 (95% CI, 0.87-1.42), 2.01 (95% CI, 1.14-3.54) in patients with eGFR ≥90, 60 to 89, 30 to 59, 15 to 29, and <15 mL/min per 1.73 m(2), respectively. Use of warfarin was associated with lower risk of stroke / thromboembolism in patients with eGFR ≥15 mL/min per 1.73 m(2); hazard ratios 0.57 (95% CI, 0.43-0.76), 0.57 (95% CI, 0.51-0.64), 0.48 (95% CI, 0.44-0.54), 0.60 (95% CI, 0.45-0.80) in patients with eGFR ≥90, 60 to 89, 30 to 59, and 15 to 29 mL/min per 1.73 m(2), respectively. Use of warfarin was not associated with lower risk of stroke / thromboembolism in patients with eGFR <15 mL/min per 1.73 m(2); hazard ratio 1.18 (95% CI, 0.58-2.40). In patients with atrial fibrillation, the risk of stroke and bleeding was associated with levels of renal function. Warfarin treatment was associated with higher risk of bleeding in all eGFR groups and lower risk of stroke in patients with eGFR ≥15 mL/min per 1.73 m(2).
27758943	0	14	Renal Function	T042	C0232804
27758943	23	27	Risk	T078	C0035647
27758943	31	37	Stroke	T047	C0038454
27758943	42	50	Bleeding	T046	C0019080
27758943	54	62	Patients	T101	C0030705
27758943	68	87	Atrial Fibrillation	T047	C0004238
27758943	92	118	Observational Cohort Study	T081	C0009247
27758943	146	150	risk	T078	C0035647
27758943	154	160	stroke	T047	C0038454
27758943	163	178	thromboembolism	T046	C0040038
27758943	183	191	bleeding	T046	C0019080
27758943	192	207	associated with	T080	C0332281
27758943	216	230	renal function	T042	C0232804
27758943	234	242	patients	T101	C0030705
27758943	248	267	atrial fibrillation	T047	C0004238
27758943	276	280	risk	T078	C0035647
27758943	284	290	stroke	T047	C0038454
27758943	295	303	bleeding	T046	C0019080
27758943	304	319	associated with	T080	C0332281
27758943	320	338	warfarin treatment	T061	C0750388
27758943	351	387	estimated glomerular filtration rate	T059	C3811844
27758943	389	393	eGFR	T059	C3811844
27758943	395	401	groups	T078	C0441833
27758943	433	445	cohort study	T081	C0009247
27758943	459	467	patients	T101	C0030705
27758943	484	515	nonvalvular atrial fibrillation	T047	C0004238
27758943	549	553	eGFR	T059	C3811844
27758943	573	581	patients	T101	C0030705
27758943	603	607	eGFR	T059	C3811844
27758943	621	629	baseline	T081	C1442488
27758943	635	641	levels	T080	C0441889
27758943	651	655	eGFR	T059	C3811844
27758943	661	676	associated with	T080	C0332281
27758943	684	688	risk	T078	C0035647
27758943	692	698	stroke	T047	C0038454
27758943	701	716	thromboembolism	T046	C0040038
27758943	721	729	bleeding	T046	C0019080
27758943	738	746	warfarin	T109,T121,T131	C0043031
27758943	751	766	associated with	T080	C0332281
27758943	774	782	bleeding	T046	C0019080
27758943	783	787	risk	T078	C0035647
27758943	795	799	eGFR	T059	C3811844
27758943	800	806	groups	T078	C0441833
27758943	808	821	hazard ratios	T081	C2985465
27758943	832	851	confidence interval	T081	C0009667
27758943	853	855	CI	T081	C0009667
27758943	880	882	CI	T081	C0009667
27758943	906	908	CI	T081	C0009667
27758943	932	934	CI	T081	C0009667
27758943	958	960	CI	T081	C0009667
27758943	976	984	patients	T101	C0030705
27758943	990	994	eGFR	T059	C3811844
27758943	1081	1089	warfarin	T109,T121,T131	C0043031
27758943	1094	1109	associated with	T080	C0332281
27758943	1116	1120	risk	T078	C0035647
27758943	1124	1130	stroke	T047	C0038454
27758943	1133	1148	thromboembolism	T046	C0040038
27758943	1152	1160	patients	T101	C0030705
27758943	1166	1170	eGFR	T059	C3811844
27758943	1197	1210	hazard ratios	T081	C2985465
27758943	1221	1223	CI	T081	C0009667
27758943	1247	1249	CI	T081	C0009667
27758943	1273	1275	CI	T081	C0009667
27758943	1299	1301	CI	T081	C0009667
27758943	1317	1325	patients	T101	C0030705
27758943	1331	1335	eGFR	T059	C3811844
27758943	1417	1425	warfarin	T109,T121,T131	C0043031
27758943	1434	1449	associated with	T080	C0332281
27758943	1456	1460	risk	T078	C0035647
27758943	1464	1470	stroke	T047	C0038454
27758943	1473	1488	thromboembolism	T046	C0040038
27758943	1492	1500	patients	T101	C0030705
27758943	1506	1510	eGFR	T059	C3811844
27758943	1537	1549	hazard ratio	T081	C2985465
27758943	1560	1562	CI	T081	C0009667
27758943	1579	1587	patients	T101	C0030705
27758943	1593	1612	atrial fibrillation	T047	C0004238
27758943	1618	1622	risk	T078	C0035647
27758943	1626	1632	stroke	T047	C0038454
27758943	1637	1645	bleeding	T046	C0019080
27758943	1650	1665	associated with	T080	C0332281
27758943	1676	1690	renal function	T042	C0232804
27758943	1692	1710	Warfarin treatment	T061	C0750388
27758943	1715	1730	associated with	T080	C0332281
27758943	1731	1737	higher	T080	C0205250
27758943	1738	1742	risk	T078	C0035647
27758943	1746	1754	bleeding	T046	C0019080
27758943	1762	1766	eGFR	T059	C3811844
27758943	1767	1773	groups	T078	C0441833
27758943	1778	1783	lower	T080	C0205251
27758943	1784	1788	risk	T078	C0035647
27758943	1792	1798	stroke	T047	C0038454
27758943	1802	1810	patients	T101	C0030705
27758943	1816	1820	eGFR	T059	C3811844